Sees FY23 revenue $3.675B-$3.875B, consensus $3.76B.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JAZZ:
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance
- Sutro Biopharma appoints Borgman as Chief Medical Officer
- Avadel says Federal Circuit Court of Appeals denied Jazz appeal
- 3 Top Marijuana Stocks, According to Analysts
- Jazz Pharmaceuticals, Zymeworks report 84% survival for zanidatamab in mGEA